Study of SAT-3247 Compared to Placebo for Patients with Duchenne Muscular Dystrophy Who Can Walk
BelgiumTitle: Long-term safety and effectiveness study of ulviprubart in patients with inclusion body myositis who completed previous treatment
BelgiumStudy on the Effects of Casimersen and Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
BelgiumStudy on the Safety and Effects of Delandistrogene Moxeparvovec in Children Under 4 with Duchenne Muscular Dystrophy
BelgiumStudy on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy
BelgiumStudy on Long-Term Safety and Effectiveness of Vamorolone in Boys with Duchenne Muscular Dystrophy Who Completed Previous Vamorolone Studies
BelgiumStudy to Determine the Best Dose of Vesleteplirsen for Patients with Duchenne Muscular Dystrophy Suitable for Exon 51-Skipping Treatment
BelgiumStudy on the Effectiveness and Safety of Avalglucosidase Alfa for Babies with Infantile-Onset Pompe Disease
BelgiumStudy of DYNE-251 safety and effectiveness in patients with Duchenne muscular dystrophy who are candidates for exon 51 skipping treatment
BelgiumStudy on the Effects of Fordadistrogene Movaparvovec for Patients with Duchenne Muscular Dystrophy
BelgiumStudy on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease
BelgiumStudy on the Safety and Effectiveness of ABC008 for Patients with Inclusion Body Myositis
Belgiumpowered by
